摘要
The explosion of new therapeutics in metastatic castrate-resistant prostatecancer （mCRPC） is unprecedented, but much more work needs to be done before we are satisfied. Six phase III trials with an overall survival impact have now been reported （Table 1）.1-6 Four of these trials were exclusively or predominantly in the mCRPC post-docetaxel space （MDV3100, abiraterone, 223radium and cabazitaxel）. The 223radium trial also uniquely offered therapy to patients who were unsuitable for or refused docetaxel. The sipuleucel-T trial focused on mCRPC patients who were asymptomatic or minimally symptomatic; most of these patients were chemotherapy naive.
The explosion of new therapeutics in metastatic castrate-resistant prostatecancer （mCRPC） is unprecedented, but much more work needs to be done before we are satisfied. Six phase III trials with an overall survival impact have now been reported （Table 1）.1-6 Four of these trials were exclusively or predominantly in the mCRPC post-docetaxel space （MDV3100, abiraterone, 223radium and cabazitaxel）. The 223radium trial also uniquely offered therapy to patients who were unsuitable for or refused docetaxel. The sipuleucel-T trial focused on mCRPC patients who were asymptomatic or minimally symptomatic; most of these patients were chemotherapy naive.
